Ascentage Pharma
800 King Farm Blvd.
Suite 300
Rockville
MD
20850
United States
Website: http://www.ascentagepharma.com/
129 articles with Ascentage Pharma
-
Ascentage Pharma to Present Latest Results from Three Preclinical Studies at 2023 American Association for Cancer Research Annual Meeting
3/14/2023
Ascentage Pharma (6855.HK) today announced that the latest results from three preclinical studies of the company's novel third-generation BCR-ABL inhibitor olverembatinib (HQP1351) and two key assets of Ascentage Pharma's apoptosis-targeting pipeline, the Bcl-2 inhibitor lisaftoclax (APG-2575) and the MDM2-p53 inhibitor alrizomadlin (APG-115), have been selected for presentations at the 2023 American Association of Cancer Research Annual Meeting (AACR 2023).
-
China's First and Only Approved Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List
1/19/2023
Ascentage Pharma and Innovent Biologics, Inc., announced that the novel drug olverembatinib has been included into the China 2022 National Reimbursement Drug List（NRDL), for the treatment of T315I-mutant chronic-phase chronic myeloid leukemia and accelerated-phase CML.
-
Ascentage Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/5/2023
Ascentage Pharma announced that its Chairman and CEO, Dr. Dajun Yang, has accepted an invitation to speak at the 41st Annual J.P. Morgan Healthcare Conference, at 08:30 AM, January 11, 2023, Pacific Time, to provide an update on Ascentage Pharma's progress with its proprietary innovation and global R&D.
-
Live from ASH 2022 | Ascentage Pharma Presents Latest Data of APG-2575, Including Encouraging Results of the Combination with BTKi in Patients with R/R CLL/SLL
12/13/2022
Ascentage Pharma announced that it has released preliminary results from a global Phase II study of lisaftoclax, a key member of the company's apoptosis-targeting pipeline, as a monotherapy or in combination with CALQUENCE® or rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, in an oral presentation at the ASH 64th Annual Meeting & Exposition.
-
Live from ASH 2022 | Ascentage Pharma Delivers Oral Report on the First Dataset from the US Study of Olverembatinib (HQP1351) with Promising Efficacy Observed in Patients Who Failed Prior Treatment with Ponatinib
12/12/2022
Ascentage Pharma announced that it has released preliminary results of olverembatinib in patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, in an Oral Presentation at the American Society of Hematology 64th Annual Meeting and Exposition, marking the first data readout from the US study.
-
Live from ASH 2022 | Ascentage Pharma Delivers Oral Presentations on Chinese Studies of Olverembatinib (HQP1351) at the ASH Annual Meeting for the Fifth Year, with Data Further Validating the Drug's Long-Term Efficacy and Safety
12/11/2022
Ascentage Pharma announced that it has delivered two Oral Presentations on Chinese studies of the company's novel drug candidate olverembatinib at the American Society of Hematology 64th Annual Meeting and Exposition.
-
Ascentage Pharma Announces IND Approval in China for Phase I Study of APG-5918 in Patients with Advanced Solid Tumors or Hematologic Malignancies
11/9/2022
Ascentage Pharma (6855.HK) today announced that its novel inhibitor of the embryonic ectoderm development (EED) protein, APG-5918, has been approved by the Center for Drug Evaluations (CDE) of China National Medical Products Administration (NMPA) to enter a Phase I study in patients with advanced solid tumors or hematologic malignancies.
-
AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB
11/6/2022
Ascentage Pharma announced that it has released results from a Phase I study of the investigational inhibitor of apoptosis protein antagonist APG-1387 in Chinese patients with chronic hepatitis B, in an oral presentation at the 73rd American Association for the Study of Liver Diseases Annual Meeting.
-
ASH 2022 | Ascentage Pharma to Present Initial Data of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Combination with BTK Inhibitors for the Treatment of R/R CLL/SLL, Including an ORR of 98%, in an Oral Report at the ASH Annual Meeting
11/3/2022
Ascentage Pharma announced that the initial results from a global Phase II study of the company's Bcl-2-selective inhibitor, lisaftoclax, as a monotherapy or in combination regimens for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, have been selected for an oral presentation at the 64th American Society of Hematology Annual Meeting.
-
ASH 2022 | Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, at the ASH Annual Meeting
11/3/2022
Ascentage Pharma announced that the updated results from three studies of the company's novel drug candidate, olverembatinib, have been selected for oral presentations at the 64th American Society of Hematology Annual Meeting.
-
AASLD 2022 | Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting
10/19/2022
Ascentage Pharma (6855.HK) today announced that it will release results from the Phase I first-in-human study of APG-1387, the company's investigational inhibitor of apoptosis protein (IAP) antagonist, in patients with chronic hepatitis B (CHB), in an oral presentation at the 73th American Association for the Study of Liver Diseases Annual Meeting (AASLD 2022).
-
Ascentage Pharma Announces 2022 Interim Results
8/26/2022
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its 2022 interim results.
-
Ascentage Pharma and Tanner Pharma Group Initiate a Global Innovative Named Patient Program
7/25/2022
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Tanner Pharma Group ("Tanner Pharma"), a global pharmaceutical services provider of specialty access solutions, have jointly launched an innovative Named Patient Program (NPP) for olverembatinib.
-
Ascentage Pharma Announces Clinical Trial Application for Olverembatinib (HQP1351) Approved in Canada
7/21/2022
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Phase Ib study of Ascentage Pharma's novel drug candidate, olverembatinib (HQP1351).
-
Ascentage Pharma and Innovent Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
7/19/2022
Ascentage Pharma and Innovent Biologics, Inc. announce that the Center for Drug Evaluation of China National Medical Products Administration has accepted and granted Priority Review designation to a New Drug Application that will support the full approval of olverembatinib in patients with chronic-phase chronic myeloid leukemia who are resistant and/or intolerant of first- and second-generation tyrosine kinase inhibitors.
-
Innovent and Ascentage Pharma Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
7/19/2022
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), and Ascentage Pharma (6855.HK), today announce that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has accepted and granted Priority Review designation[1].
-
Ascentage Pharma Announces IND Clearance by the US FDA for First-in-Human Study of Novel EED Inhibitor APG-5918
6/30/2022
Ascentage Pharma announced that its novel inhibitor of the embryonic ectoderm development protein, APG-5918, has been cleared by the US Food and Drug Administration to enter a first-in-human study that will assess the safety, pharmacokinetics, and preliminary efficacy of APG-5918 in patients with solid tumors or hematologic malignancies.
-
EHA 2022 | Ascentage Pharma Releases Encouraging Results of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
6/13/2022
Ascentage Pharma announced that it has released results from a Phase I study of the company's novel Bcl-2-selective inhibitor lisaftoclax in Chinese patients with relapsed/refractory non-Hodgkin lymphoma at the 2022 European Hematology Association Hybrid Congress.
-
CEL-SCI Corporation, Jazz Pharmaceuticals, CARsgen and Ascentage Pharma presented clinical trial data at the American Society of Clinical Oncology 2022 Annual Meeting.
-
ASCO 2022 | The First Dataset of Olverembatinib (HQP1351) in Patients with GIST Demonstrates Therapeutic Potential with a Clinical Benefit Rate of 83.3%
6/7/2022
Ascentage Pharma announced that it has released the latest results from a Phase Ib/II study of the third-generation tyrosine kinase inhibitor olverembatinib in patients with metastatic gastrointestinal stromal tumor who were resistant to or failed prior TKI treatment, in a Poster Discussion session at the 58th American Society of Clinical Oncology Annual Meeting.